Hypervision Surgical develops medical devices that apply artificial intelligence and spectral imaging to surgery. Its platform provides surgeons with real-time, AI-driven tissue intelligence, aiming to enhance precision and patient safety by revealing anatomical and physiological information that is not visible to the human eye.
The company's core product is a real-time intraoperative spectral imaging platform. It combines on-chip spectral sensing with high-speed AI analytics, processing data at over 60 frames per second. The system is designed to integrate into existing surgical vision systems and is certified for use in both open and minimally invasive surgery.
The platform has achieved UKCA certification and received FDA clearance in 2025. Hypervision Surgical operates within the medical devices and surgery sectors, focusing on advancing the field of intraoperative imaging through its proprietary technology.
